Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024488 | 0.89 | KDM4E (0.53) | GAAFFAR4KDM4EGRM2CHRM4 | |
| SCHEMBL1022983 | 0.88 | GRM2 (0.44) | GAAFFAR4KDM4EGRM2 | |
| SCHEMBL4359206 | 0.88 | DPP4 (0.43) | GAAFFAR4KDM4EGRM2CHRM4 | |
| SCHEMBL1025401 | 0.88 | GAA (0.56) | GAAFFAR4KDM4EGRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL1026535 | 0.84 | FFAR4 (0.52) | GAAFFAR4KDM4EFFAR1 | |
| SCHEMBL4355886 | 0.84 | CHRM4 (0.48) | FFAR4CHRM4FFAR1 | |
| SCHEMBL13622681 | 0.81 | FFAR4 (0.54) | GAAFFAR4KDM4EGRM2CHRM4 | |
| SCHEMBL1023810 | 0.78 | ALDH1A1 (0.58) | KDM4E | |
| SCHEMBL1025133 | 0.77 | GAA (0.38) | GAAFFAR4GRM2CHRM4FFAR1 | |
| SCHEMBL4364982 | 0.76 | CHRM4 (0.46) | FFAR4KDM4ECHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | GAA 2377/4885FFAR4 2075/4885KDM4E 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.